Conference LibraryGated
Orbital Therapeutics · in vivo RNA delivery (acquired by BMS $1.5B)
Orbital Therapeutics · in vivo RNA / cell engineering 公司 · 2025 被 BMS 以 $1.5B 收购(per OPORD-002 P0)。对 SunVax 对标:若 Orbital modality 含 LNP/mRNA · 与 SunVax 在 delivery technology 维度部分重叠。 待 verify 后 narrow 对标精度。
- Type
- company
- Domain
- conference
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- evidence_grade
- B
- category
- in_vivo_rna_delivery
- status
- draft
- instance_tag
- sunvax-antibody-2025
- threat_level
- medium
- competes_dimensions
- in_vivo_cell_engineering,delivery_modality
- platform_tech
- in vivo RNA delivery (cell engineering modality TBD)
- acquisitions
- [object Object]
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.